<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074121</url>
  </required_header>
  <id_info>
    <nct_id>NCT05074121</nct_id>
  </id_info>
  <brief_title>NAC for Attenuation of COVID-19 Symptomatology</brief_title>
  <acronym>NACinCOVID2</acronym>
  <official_title>N-acetylcysteine for Attenuation of COVID Symptomatology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Thoracic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alturix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether oral NAC is effective at attenuating&#xD;
      COVID-19 disease symptom severity and duration of symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN: Randomized double-blinded placebo-controlled trial&#xD;
&#xD;
      ELIGIBILITY&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  age 18 years and older&#xD;
&#xD;
        -  participants will need daily access to use of a smartphone for at least six weeks from&#xD;
           time of enrollment&#xD;
&#xD;
        -  Positive COVID-19 test within 10 days of date of enrollment&#xD;
&#xD;
        -  not already hospitalized for treatment of COVID&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  pregnant&#xD;
&#xD;
        -  already hospitalized for treatment of COVID&#xD;
&#xD;
      PROTOCOL&#xD;
&#xD;
        -  50:50 randomization: half of participants will take NAC, half will take placebo&#xD;
&#xD;
        -  Participants will take NAC/placebo following this outpatient protocol:&#xD;
&#xD;
        -  2400 mg x 1 PO then&#xD;
&#xD;
        -  1200 mg PO BID x 14 days&#xD;
&#xD;
        -  Participants will complete an online symptom-tracker for six weeks (daily for three&#xD;
           weeks, weekly for three weeks)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double-Blinded Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants and study team members will be masked to whether a participant is receiving the study drug or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom severity</measure>
    <time_frame>24 weeks starting the day after enrollment</time_frame>
    <description>Severity of symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom duration</measure>
    <time_frame>24 weeks starting the day after enrollment</time_frame>
    <description>Length in days of symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for higher level of care/hospitalization</measure>
    <time_frame>24 weeks starting the day after enrollment</time_frame>
    <description>Comparison between groups of rates of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <condition>COVID-19 Pneumonia</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <condition>COVID-19 Lower Respiratory Infection</condition>
  <condition>SARS-CoV2 Infection</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <condition>SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>NAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receiving intervention/study drug NAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine</description>
    <arm_group_label>NAC</arm_group_label>
    <other_name>NAC</other_name>
    <other_name>N-acetyl-cysteine</other_name>
    <other_name>Acetylcysteine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  positive COVID test &lt;= 7 days of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  already hospitalized due to COVID&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melisa Lai-Becker, MD</last_name>
    <phone>617-394-7424</phone>
    <email>melaibecker@cha.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Seufert, MD</last_name>
    <email>tseufert@cha.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Everett</city>
        <state>Massachusetts</state>
        <zip>02149</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melisa Lai-Becker, MD</last_name>
      <email>melaibecker@cha.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tom Seufert, MD</last_name>
      <email>tseufert@cha.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge Health Alliance</investigator_affiliation>
    <investigator_full_name>Melisa Lai-Becker</investigator_full_name>
    <investigator_title>Chief, CHA Everett Emergency Department; Director, CHA Division of Medical Toxicology</investigator_title>
  </responsible_party>
  <keyword>acetylcysteine</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>N-acetyl-cysteine</keyword>
  <keyword>NAC</keyword>
  <keyword>glutathione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study data used for publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Available six months after publication for one year</ipd_time_frame>
    <ipd_url>http://www.NACinCOVID.info</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

